Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
Source abstract
Abstract
Systemic gene delivery systems are needed for therapeutic application to organs that are inaccessible by percutaneous injection. Currently, the main objective is the development of a stable and non-toxic vector that can encapsulate and deliver foreign genetic material to target cells. To this end, DNA, complexed with cationic lipids i.e. DOTAP/DOPE, was encapsulated into lipid nanocapsules (LNCs) leading to the formation of stable nanocarriers (DNA LNCs) with a size inferior to 130 nm. Amphiphilic and flexible poly (ethylene glycol) (PEG) polymer coatings [PEG lipid derivative (DSPE-mPEG(2000)) or F108 poloxamer] at different concentrations were selected to make DNA LNCs stealthy. Some of these coated lipid nanocapsules were able to inhibit complement activation and were not phagocytized in vitro by macrophagic THP-1 cells whereas uncoated DNA LNCs accumulated in the vacuolar compartment of THP-1 cells. These results correlated with a significant increase of in vivo circulation time in mice especially for DSPE-mPEG(2000) 10 mm and an early half-life time (t(1/2) of distribution) 5-fold greater than for non-coated DNA LNCs (7.1 h vs 1.4 h). Finally, a tumor accumulation assessed by in vivo fluorescence imaging system was evidenced for these coated LNCs as a passive targeting without causing any hepatic damage.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer10.1016/j.biomaterials.2008.04.036 ↗
2. Activation of the complement system at the interface between blood and artificial surfaces10.1016/0142-9612(88)90066-X ↗
3. Parameters influencing the stealthiness of colloidal drug delivery systems10.1016/j.biomaterials.2006.03.039 ↗
4. A novel phase inversion-based process for the preparation of lipid nanocarriers10.1023/A:1016121319668 ↗
5. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake10.1002/jbm.a.30711 ↗
6. The encapsulation of DNA molecules within biomimetic lipid nanocapsules10.1016/j.biomaterials.2009.03.009 ↗
7. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
8. Evaluation of polyether–polyethyleneimine graft copolymers as gene transfer agents10.1038/sj.gt.3301052 ↗
9. Altered organ accumulation of oligonucleotides using polyethyleneimine grafted with poly(ethylene oxide) or pluronic as carriers10.1080/10611860290016711 ↗
10. A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles10.1089/104303402760293592 ↗
11. Pluronic block copolymers: novel functional molecules for gene therapy10.1016/S0169-409X(02)00018-2 ↗
12. The influence of lipid nanocapsule composition on their size distribution10.1016/S0928-0987(02)00241-5 ↗
13. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats10.1158/1535-7163.MCT-06-0289 ↗
14. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system10.1016/S0024-3205(97)01175-2 ↗
15. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester
16. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays10.1016/0022-1759(83)90303-4 ↗
17. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery10.1023/A:1010931127745 ↗
18. Novel long-circulating lipid nanocapsules10.1023/B:PHAM.0000045229.87844.21 ↗
19. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments10.1016/j.biomaterials.2007.05.014 ↗
20. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators10.1016/0142-9612(95)00322-3 ↗
21. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel10.1016/j.ijpharm.2007.06.014 ↗
22. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery10.1089/hum.1996.7.12-1437 ↗
23. Liposome–complement interactions in rat serum: implications for liposome survival studies10.1016/0005-2736(94)90231-3 ↗
24. Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface10.1002/elps.200410145 ↗
25. Interactions of liposomes with the reticuloendothelial system. II: nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages10.1016/0167-4889(82)90120-3 ↗
26. Biodegradable long-circulating polymeric nanospheres10.1126/science.8128245 ↗
27. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time10.1016/0014-5793(96)00452-8 ↗
28. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression10.1016/j.bbamem.2005.02.001 ↗
29. Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting10.1016/j.ijpharm.2009.05.065 ↗
30. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells10.1016/S0005-2760(97)00169-0 ↗
31. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules10.1016/S0142-9612(01)00043-6 ↗
32. Plasmid DNA-entrapped nanoparticles engineered from microemulsion precursors: in vitro and in vivo evaluation10.1021/bc0255586 ↗
33. RNAi-mediated gene silencing in non-human primates10.1038/nature04688 ↗
34. Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties10.1038/sj.gt.3300965 ↗
35. Stabilized plasmid-lipid particles: construction and characterization10.1038/sj.gt.3300821 ↗
36. Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties10.1016/S0005-2736(99)00059-0 ↗